Haemostatix is developing first-in-class clotting agents for the treatment of bleeding or ‘haemostasis’. The company has pioneered a new approach to the control of bleeding that is based on a peptide that binds to the clotting protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical and systemic products to prevent or control different forms of bleeding.

Haemostatix's products include:  PeproStat™, a topical haemostat that is applied directly to wounds to rapidly control bleeding during surgery or trauma. PeproStat has a novel mode of action that is fast and effective. The product is also stable in liquid form in contrast to the main competitor, thrombin, enabling the development of ready-to-use formulations, a key unmet need.  HaemoPlax™, a platelet substitute in development for the prevention of bleeding in leukaemic patients with platelet deficiency or ‘thrombocytopenia'. HXTC901 is a 'pro-drug' version of HaemoPlax that is activated by the enzyme thrombin at a wound site. HXTC 901 is designed to control more active bleeds in surgery or trauma. 

Haemostatix is based at BioCity, Nottingham, United Kingdom. More...